Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society).

Carsten Saft, Jean-Marc Burgunder, Matthias Dose, Hans Heinrich Jung, Regina Katzenschlager, Josef Priller, Huu Phuc Nguyen, Kathrin Reetz, Ralf Reilmann, Klaus Seppi, Georg Bernhard Landwehrmeyer
{"title":"Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society).","authors":"Carsten Saft, Jean-Marc Burgunder, Matthias Dose, Hans Heinrich Jung, Regina Katzenschlager, Josef Priller, Huu Phuc Nguyen, Kathrin Reetz, Ralf Reilmann, Klaus Seppi, Georg Bernhard Landwehrmeyer","doi":"10.1186/s42466-023-00285-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ameliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to achieve. The pharmacological treatment of motor signs (e.g. chorea) may favorably or unfavorably impact other facets of the disease phenotype (such as mood and cognition). Similarly, pharmacotherapy for behavioral issues may modify the motor phenotype. Sometimes synergistic effects can be achieved. In patients undergoing pragmatic polypharmacological therapy, emerging complaints may stem from the employed medications' side effects, a possibility that needs to be considered. It is recommended to clearly and precisely delineate the targeted signs and symptoms (e.g., chorea, myoclonus, bradykinesia, Parkinsonism, or dystonia). Evidence from randomized controlled trials (RCTs) is limited. Therefore, the guidelines prepared for the German Neurological Society (DGN) for German-speaking countries intentionally extend beyond evidence from RCTs and aim to synthesize evidence from RCTs and recommendations of experienced clinicians.</p><p><strong>Recommendations: </strong>First-line treatment for chorea is critically discussed, and a preference in prescription practice for using tiapride instead of tetrabenazine is noted. In severe chorea, combining two antidopaminergic drugs with a postsynaptic (e.g., tiapride) and presynaptic mode of action (e.g., tetrabenazine) is discussed as a potentially helpful strategy. Sedative side effects of both classes of compounds can be used to improve sleep if the highest dosage of the day is given at night. Risperidone, in some cases, may ameliorate irritability but also chorea and sleep disorders. Olanzapine can be helpful in the treatment of weight loss and chorea, and quetiapine as a mood stabilizer with an antidepressant effect.</p><p><strong>Conclusions: </strong>Since most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric/behavioral symptoms, treatment should be individually adapted.</p>","PeriodicalId":94156,"journal":{"name":"Neurological research and practice","volume":"5 1","pages":"61"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652593/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological research and practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42466-023-00285-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Ameliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to achieve. The pharmacological treatment of motor signs (e.g. chorea) may favorably or unfavorably impact other facets of the disease phenotype (such as mood and cognition). Similarly, pharmacotherapy for behavioral issues may modify the motor phenotype. Sometimes synergistic effects can be achieved. In patients undergoing pragmatic polypharmacological therapy, emerging complaints may stem from the employed medications' side effects, a possibility that needs to be considered. It is recommended to clearly and precisely delineate the targeted signs and symptoms (e.g., chorea, myoclonus, bradykinesia, Parkinsonism, or dystonia). Evidence from randomized controlled trials (RCTs) is limited. Therefore, the guidelines prepared for the German Neurological Society (DGN) for German-speaking countries intentionally extend beyond evidence from RCTs and aim to synthesize evidence from RCTs and recommendations of experienced clinicians.

Recommendations: First-line treatment for chorea is critically discussed, and a preference in prescription practice for using tiapride instead of tetrabenazine is noted. In severe chorea, combining two antidopaminergic drugs with a postsynaptic (e.g., tiapride) and presynaptic mode of action (e.g., tetrabenazine) is discussed as a potentially helpful strategy. Sedative side effects of both classes of compounds can be used to improve sleep if the highest dosage of the day is given at night. Risperidone, in some cases, may ameliorate irritability but also chorea and sleep disorders. Olanzapine can be helpful in the treatment of weight loss and chorea, and quetiapine as a mood stabilizer with an antidepressant effect.

Conclusions: Since most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric/behavioral symptoms, treatment should be individually adapted.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
亨廷顿氏病的对症治疗选择(德国神经学会指南)。
简介:改善亨廷顿舞蹈病(HD)的症状和体征对护理至关重要,但可能具有挑战性且难以实现。运动体征(如舞蹈病)的药物治疗可能对疾病表型的其他方面(如情绪和认知)产生有利或不利的影响。同样,针对行为问题的药物治疗可能会改变运动表型。有时可以实现协同效应。在接受实用多种药物治疗的患者中,新出现的主诉可能源于所使用药物的副作用,这是一种需要考虑的可能性。建议清晰准确地描述目标体征和症状(如舞蹈病、肌阵挛、运动迟缓、帕金森病或肌张力障碍)。随机对照试验(RCTs)的证据有限。因此,为德语国家的德国神经学学会(DGN)准备的指南有意超越随机对照试验的证据,旨在综合随机对照试验的证据和有经验的临床医生的建议。建议:对舞蹈病的一线治疗进行了批判性的讨论,并注意到在处方实践中优先使用噻必利而不是丁苯那嗪。在严重的舞蹈病中,联合两种抗多巴胺能药物与突触后(例如,噻必利)和突触前的作用模式(例如,丁苯那嗪)被认为是一种潜在的有用策略。如果在晚上给药,这两类化合物的镇静副作用都可以用来改善睡眠。在某些情况下,利培酮可以改善易怒,但也可以改善舞蹈病和睡眠障碍。奥氮平有助于减肥和舞蹈病的治疗,喹硫平是一种具有抗抑郁作用的情绪稳定剂。结论:由于大多数HD患者同时患有明显的运动体征和明显的精神/行为症状,治疗应个体化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.40
自引率
0.00%
发文量
0
审稿时长
14 weeks
期刊最新文献
Ischemia/reperfusion injury in acute human and experimental stroke: focus on thrombo-inflammatory mechanisms and treatments. Letter to the editor in response to Professor Josef Finsterer. MS brain health quality standards: a survey on the reality in clinical practice in Germany. Chikungunya-related Guillain-Barre syndrome is most commonly demyelinating and affects multiple cranial nerves. Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1